Fusobacterium russii

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Fusobacterium russii is a Gram-negative, non-spore-forming, strictly anaerobic, rod-shaped bacterium. It has been detected in at least 8 gut microbiome compilation studies or metastudies. Fusobacterium russii is probably a common, although minor, coloniser of the gut. (Gharbia2010aBergey)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Gharbia2010aBergey);
    Character Response
  • 💧
  • Bile tolerance:
  • Doesn't tolerate bile
  • Active enzymes:
  • acid phosphatase;
    • SPECIAL FEATURES (Gharbia2010aBergey);
    Character Response
  • ✓
  • Metabolites produced:
  • indole;
  • ✗
  • Haemolysis:
  • absent
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Gharbia2010aBergey); (Goldstein2017); (Citron2012); (Goldstein2006c); (Citron2001); (Goldstein2000); (Goldstein1999a); (Goldstein1999b);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; imipenem; meropenem; penicillin; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefotaxime;
  • Macrolides:
  • telithromycin;
  • roxithromycin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline; tigecycline;
  • Quinolines:
  • gatifloxacin; levofloxacin; trovafloxacin;
  • sparfloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; telithromycin;

  • Moore, WEC & LV Holdeman (1974). Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 27: 961-979.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Fusobacteria Class:  Fusobacteriia Order:  Fusobacteriales Family:  Fusobacteriaceae Genus:  Fusobacterium Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    Bile reaction(%):  neg
    		Aesculin:  neg Urea:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Mannose:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Fructose:  neg Glucose:  neg Mannose:  neg Lactose:  neg Maltose:  neg Raffinose:  neg Sucrose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg ArgDH:  neg GluDC:  neg AlanineAA:  neg GluGluAA:  neg GlyAA:  neg LeuAA:  neg LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  w AcidP:  + Esterase(C4):  neg EstLip(C8):  neg Lipase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Indole:  +
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (≤0.015-0.25)
    amp-sulb:  S(MIC50): 2, MIC90: -, RNG: (0.5–4)
    penicillin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.03–0.06)
    penicillin_G:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.015-0.06)
    piper-taz:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.03)
    imipenem:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06-4)
    meropenem:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.03)
    cefotaxime:  S(MIC50): 0.06, MIC90: 0.25, RNG: (≤0.015-0.25)
    azithromycin:  Var(MIC50): 0.25, MIC90: 32, RNG: (0.03-32)
    erythromycin:  Var(MIC50): 4, MIC90: >32, RNG: (1–>32)
    clarithromycin:  Var(MIC50): 4, MIC90: >32, RNG: (2->32)
    roxithromycin:  R(MIC50): 8, MIC90: >32, RNG: (≤0.015->32)
    telithromycin:  S(MIC50): 1, MIC90: -, RNG: (0.5–2)
    linezolid:  S(MIC50): 1, MIC90: 1, RNG: (1–1)
    ciprofloxacin:  Var(MIC50): 4, MIC90: 16, RNG: (0.125->32)
    gatifloxacin:  S(MIC50): 1, MIC90: 8, RNG: (0.06-8)
    levofloxacin:  S(MIC50): 0.5, MIC90: -, RNG: (0.25–1)
    moxifloxacin:  Var(MIC50): 8, MIC90: 8, RNG: (8–16)
    sparfloxacin:  R(MIC50): >8, MIC90: >8, RNG: (≤0.03–>8)
    trovafloxacin:  S(MIC50): 4, MIC90: 4, RNG: (0.5-4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.06, MIC90: 0.125, RNG: (≤0.015–0.125)
    minocycline:  S(MIC50): 0.06, MIC90: 0.06, RNG: (≤0.015–0.125)
    tetracycline:  S(MIC50): 0.25, MIC90: 0.25, RNG: (≤0.015–1)
    tigecycline:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.03–0.25)
    vancomycin:  R(MIC50): 512, MIC90: >8, 192)
    metronidazole:  S(MIC50): 0.125, MIC90: 0.25, RNG: (≤0.015-0.25)
    clindamycin:  S(MIC50): 0.03, MIC90: 0.05, RNG: (≤0.015-0.125)

    References

    SPECIFIC REFERENCES FOR FUSOBACTERIUM RUSSII
  • Gharbia2010aBergey - Bergey's manual of systematic bacteriology. Vol. 4, The Fusobacteria. Family Fusobacteriaceae, Genus I. Fusobacterium
  • Salyers1977 - Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon
  • Goldstein2017 - In Vitro Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds.
  • Citron2012 - In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Citron2001 - Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR FUSOBACTERIUM RUSSII
  • Benno1986 - Comparison of the fecal microflora in rural Japanese and urban Canadians.
  • Benno1989 - Comparison of fecal microflora of elderly persons in rural and urban areas of Japan.
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • Finegold1974 - Effect of diet on human fecal flora: comparison of Japanese and American diets
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Moore1974 - Human fecal flora: the normal flora of 20 Japanese-Hawaiians.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • ...............................
    • Added: April 08, 2021